Join
Albireo Pharma Inc. logo

ALBO

NASDAQ

Albireo Pharma Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2007
$44.29-0.01 (-0.02%)
News25/Ratings6

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.

Latest news

25 items

ALBO FAQ

7 questions
  • What does Albireo Pharma Inc. do?
    Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic...
  • Where does ALBO stock trade?
    Albireo Pharma Inc. (ALBO) is listed on NASDAQ.
  • What sector and industry is ALBO in?
    Albireo Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Albireo Pharma Inc. go public?
    Albireo Pharma Inc. (ALBO) completed its IPO in 2007.
  • What are analysts saying about ALBO?
    Albireo Pharma Inc. has had 6 recent analyst actions on file. The most recent action was from Wedbush: Neutral with a $4200.00 price target on 2023-01-09. Recent price targets cluster around $4200.00.
  • What companies are similar to ALBO?
    Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALBO side-by-side with any of them on Quantisnow.
  • How can I track ALBO on Quantisnow?
    Quantisnow aggregates Albireo Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALBO to receive live email and push alerts on every new disclosure.